PremiumCompany AnnouncementsRenovoRx Reports Strong Q1 2025 Financial Results RenovoRx reports Q1 EPS (8c), consensus (8c) RenovoRx announces Johns Hopkins initiated for TIGeR-PaC Phase 3 trial PremiumRatingsRenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity RenovoRx initiated with a Buy at H.C. Wainwright RenovoRx advnaces RenovoCath commercialization PremiumThe FlyRenovoRx receives first purchase orders for FDA-cleared RenovoCath RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial RenovoRx reports Q3 net loss $2.5M vs $1.4M last year 
